Citadel Advisors
PTCT icon

Citadel Advisors’s PTC Therapeutics PTCT Stock Holding History

Citadel Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
17,400
+5,700
+49% +$404K ﹤0.01% 7269
2025
Q4 		$889K Sell
11,700
-12,300
-51% -$894K ﹤0.01% 7646
2025
Q3 		$1.47M Sell
24,000
-10,800
-31% -$563K ﹤0.01% 6713
2025
Q2 		$1.7M Buy
34,800
+22,500
+183% +$1.07M ﹤0.01% 6028
2025
Q1 		$627K Sell
12,300
-4,600
-27% -$230K ﹤0.01% 7979
2024
Q4 		$763K Buy
16,900
+2,100
+14% +$89.9K ﹤0.01% 7604
2024
Q3 		$549K Buy
14,800
+6,200
+72% +$208K ﹤0.01% 8061
2024
Q2 		$263K Sell
8,600
-92,000
-91% -$2.98M ﹤0.01% 9399
2024
Q1 		$2.93M Buy
100,600
+80,000
+388% +$2.24M ﹤0.01% 4832
2023
Q4 		$568K Buy
20,600
+12,500
+154% +$286K ﹤0.01% 7813
2023
Q3 		$182K Sell
8,100
-5,900
-42% -$219K ﹤0.01% 10076
2023
Q2 		$569K Sell
14,000
-16,400
-54% -$802K ﹤0.01% 7660
2023
Q1 		$1.47M Sell
30,400
-2,300
-7% -$105K ﹤0.01% 5950
2022
Q4 		$1.25M Buy
32,700
+4,300
+15% +$179K ﹤0.01% 6385
2022
Q3 		$1.43M Buy
28,400
+9,500
+50% +$465K ﹤0.01% 6247
2022
Q2 		$757K Buy
+18,900
New +$663K ﹤0.01% 7670
2021
Q3 		– Sell
-30,600
Closed -$1.29M – 14470
2021
Q2 		$1.29M Buy
30,600
+10,200
+50% +$437K ﹤0.01% 7678
2021
Q1 		$966K Buy
20,400
+7,800
+62% +$463K ﹤0.01% 8205
2020
Q4 		$769K Sell
12,600
-9,600
-43% -$566K ﹤0.01% 7332
2020
Q3 		$1.04M Sell
22,200
-10,200
-31% -$502K ﹤0.01% 5964
2020
Q2 		$1.64M Sell
32,400
-13,600
-30% -$668K ﹤0.01% 4913
2020
Q1 		$2.05M Buy
46,000
+11,000
+31% +$554K ﹤0.01% 4103
2019
Q4 		$1.68M Sell
35,000
-26,100
-43% -$1.11M ﹤0.01% 4697
2019
Q3 		$2.07M Buy
61,100
+17,500
+40% +$762K ﹤0.01% 4438
2019
Q2 		$1.96M Buy
43,600
+22,700
+109% +$896K ﹤0.01% 4545
2019
Q1 		$787K Sell
20,900
-9,700
-32% -$326K ﹤0.01% 6014
2018
Q4 		$1.05M Sell
30,600
-15,600
-34% -$561K ﹤0.01% 5221
2018
Q3 		$2.17M Buy
46,200
+10,000
+28% +$414K ﹤0.01% 4270
2018
Q2 		$1.22M Buy
36,200
+9,200
+34% +$287K ﹤0.01% 4871
2018
Q1 		$731K Buy
27,000
+4,800
+22% +$122K ﹤0.01% 5263
2017
Q4 		$370K Sell
22,200
-56,400
-72% -$955K ﹤0.01% 6120
2017
Q3 		$1.57M Buy
78,600
+47,500
+153% +$930K ﹤0.01% 3701
2017
Q2 		$570K Sell
31,100
-12,000
-28% -$162K ﹤0.01% 4930
2017
Q1 		$424K Sell
43,100
-8,300
-16% -$100K ﹤0.01% 5299
2016
Q4 		$561K Buy
51,400
+6,400
+14% +$67.1K ﹤0.01% 4718
2016
Q3 		$630K Buy
45,000
+14,400
+47% +$117K ﹤0.01% 4497
2016
Q2 		$215K Buy
30,600
+1,200
+4% +$8.8K ﹤0.01% 5723
2016
Q1 		$189K Sell
29,400
-13,000
-31% -$226K ﹤0.01% 5680
2015
Q4 		$1.37M Buy
42,400
+11,300
+36% +$333K ﹤0.01% 3198
2015
Q3 		$830K Buy
31,100
+9,900
+47% +$423K ﹤0.01% 4063
2015
Q2 		$1.02M Buy
21,200
+10,000
+89% +$583K ﹤0.01% 3941
2015
Q1 		$682K Buy
+11,200
New +$683K ﹤0.01% 4467

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors's PTCT Position: Q1 2026 in Review

Citadel Advisors reduced its PTC Therapeutics (PTCT) stake by 67% in Q1 2026, selling an estimated $54.5M and leaving 385,199 shares worth $26.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1996.

Citadel Advisors first reported a position in PTCT in Q1 2014 and has held it in 44 quarters since. The position peaked at $106M in Q3 2025. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Citadel Advisors held 385,199 shares of PTC Therapeutics worth $26.2M as of Q1 2026.
  • Citadel Advisors sold 769,256 PTC Therapeutics shares in Q1 2026, an estimated $54.5M.
  • PTC Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #1996 holding.
  • Citadel Advisors first reported a position in PTC Therapeutics in Q1 2014 and has held it in 44 quarters since.
  • Citadel Advisors's PTC Therapeutics position peaked at $106M in Q3 2025.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.